Orphan status for Shire’s experimental UC drug
US regulators have granted Shire’s investigational therapy SHP647 orphan status for the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC).
Read More
Tag: ulcerative coliti
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
